Contemporary Adjuvant Chemotherapy for Intraductal Papillary Mucinous Neoplasms

What is the survival benefit associated with contemporary adjuvant chemotherapy regimens after resection in adenocarcinoma arising from intraductal papillary mucinous neoplasms (A-IPMNs)?In this cohort study among 1321 patients with A-IPMNs, adjuvant chemotherapy was not associated with improved overall survival, regardless of adjuvant chemotherapy type.Contemporary adjuvant chemotherapy was not associated with improved overall survival, and a randomized clinical trial is indicated.

Corresponding Author: Sanjay Pandanaboyana, MPhil, Department of Hepato-Pancreato-Biliary and Transplant Surgery, Freeman Hospital, Freeman Road, Newcastle Upon Tyne NE7 7DN, United Kingdom (sanjay.pandanaboyana@ncl.ac.uk).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.